Arixa: Breaking resistance with oral beta lactamase inhibitors
Arixa's prodrug chemistry for oral beta-lactamase inhibitors
Arixa has made an IV antibiotic oral with prodrug chemistry.
Arixa Pharmaceuticals Inc. is modifying diazabicyclooctanes, a class of β-lactamase inhibitors that suffer from poor absorption across the GI tract, for use in combination with β-lactam antibiotics to treat Gram-negative infections.
No oral β-lactamase inhibitors have received FDA approval since the first in 1984: clavulanate. And, according to Arixa